Research Analysts Set Expectations for Vericel Q3 Earnings

Vericel Corporation (NASDAQ:VCEL) – Research analysts at HC Wainwright lowered their Q3 2026 earnings estimates for Vericel in a report released on Friday, July 31st. HC Wainwright analyst S. Ramakanth now anticipates that the biotechnology company will post earnings of $0.02 per share for the quarter, down from their previous forecast of $0.12. HC Wainwright has a “Buy” rating and a $70.00 price target on the stock. The consensus estimate for Vericel’s current full-year earnings is $0.49 per share. HC Wainwright also issued estimates for Vericel’s Q1 2027 earnings at ($0.13) EPS, FY2027 earnings at $0.68 EPS, FY2028 earnings at $1.13 EPS, FY2029 earnings at $1.61 EPS and FY2030 earnings at $2.21 EPS.

Other analysts have also issued reports about the stock. Weiss Ratings upgraded shares of Vericel from a “sell (d+)” rating to a “hold (c)” rating in a research note on Friday. Wall Street Zen upgraded shares of Vericel from a “hold” rating to a “buy” rating in a research note on Saturday, July 18th. TD Cowen increased their price target on shares of Vericel from $55.00 to $58.00 and gave the company a “buy” rating in a report on Friday. Truist Financial reissued a “buy” rating and set a $58.00 price target (up from $54.00) on shares of Vericel in a research report on Friday. Finally, Canaccord Genuity Group set a $60.00 price objective on shares of Vericel in a report on Thursday. Four equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $58.40.

Vericel Price Performance

Shares of Vericel stock opened at $46.05 on Tuesday. The stock has a market cap of $2.36 billion, a price-to-earnings ratio of 97.98 and a beta of 1.06. The firm’s 50-day moving average is $42.18 and its 200 day moving average is $37.46. Vericel has a 1 year low of $28.95 and a 1 year high of $49.32.

Vericel (NASDAQ:VCEL) last posted its quarterly earnings results on Thursday, July 30th. The biotechnology company reported $0.04 earnings per share for the quarter, topping the consensus estimate of ($0.03) by $0.07. Vericel had a return on equity of 6.91% and a net margin of 7.91%.The company had revenue of $77.46 million for the quarter, compared to the consensus estimate of $72.70 million. During the same quarter in the prior year, the business posted ($0.01) EPS. The firm’s quarterly revenue was up 22.5% compared to the same quarter last year.

Institutional Investors Weigh In On Vericel

A number of large investors have recently made changes to their positions in VCEL. Kestra Advisory Services LLC bought a new position in shares of Vericel in the 4th quarter worth approximately $27,000. Quarry LP purchased a new stake in Vericel during the fourth quarter valued at approximately $31,000. Farther Finance Advisors LLC grew its position in shares of Vericel by 116.5% during the 4th quarter. Farther Finance Advisors LLC now owns 970 shares of the biotechnology company’s stock valued at $35,000 after acquiring an additional 522 shares during the period. Truvestments Capital LLC increased its stake in shares of Vericel by 175.4% in the 4th quarter. Truvestments Capital LLC now owns 1,534 shares of the biotechnology company’s stock worth $55,000 after purchasing an additional 977 shares in the last quarter. Finally, Empowered Funds LLC bought a new position in Vericel in the 4th quarter worth $58,000.

Insider Activity at Vericel

In related news, insider Jonathan Siegal sold 4,500 shares of the firm’s stock in a transaction that occurred on Thursday, July 30th. The shares were sold at an average price of $48.90, for a total value of $220,050.00. Following the sale, the insider owned 1,078 shares in the company, valued at approximately $52,714.20. This trade represents a 80.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Sean C. Flynn sold 15,000 shares of Vericel stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $45.64, for a total transaction of $684,600.00. Following the completion of the sale, the insider directly owned 1,647 shares of the company’s stock, valued at approximately $75,169.08. This trade represents a 90.11% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 52,232 shares of company stock worth $2,304,217. Company insiders own 7.60% of the company’s stock.

Vericel Company Profile

Vericel Corporation is a biotechnology company specializing in the development, manufacturing and commercialization of cell-based therapies for patients with severe diseases and conditions. The company’s expertise lies in regenerative medicine, where it harnesses the power of autologous cell processing to create products designed to restore function and promote healing in damaged tissues.

Vericel currently markets two FDA-approved therapies. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is indicated for the repair of symptomatic cartilage defects of the knee in adult patients.